Citius Pharmaceuticals, Inc.CTXRNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P49
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -2.55% |
| Q3 2025 | 1.25% |
| Q2 2025 | -56.95% |
| Q1 2025 | 77.08% |
| Q4 2024 | -27.03% |
| Q3 2024 | 5.47% |
| Q2 2024 | -23.35% |
| Q1 2024 | 37.53% |
| Q4 2023 | -9.05% |
| Q3 2023 | -23.43% |
| Q2 2023 | -20.36% |
| Q1 2023 | 37.19% |
| Q4 2022 | -10.67% |
| Q3 2022 | -21.09% |
| Q2 2022 | 41.60% |
| Q1 2022 | -36.75% |
| Q4 2021 | 137.89% |
| Q3 2021 | 4.11% |
| Q2 2021 | 42.05% |
| Q1 2021 | -74.94% |
| Q4 2020 | 316.05% |
| Q3 2020 | -43.72% |
| Q2 2020 | 31.17% |
| Q1 2020 | -24.34% |
| Q4 2019 | 32.06% |
| Q3 2019 | -27.06% |
| Q2 2019 | 62.73% |
| Q1 2019 | -19.56% |
| Q4 2018 | 21.60% |
| Q3 2018 | 123.11% |
| Q2 2018 | -77.36% |
| Q1 2018 | 467.14% |
| Q4 2017 | 27.82% |
| Q3 2017 | 148.90% |
| Q2 2017 | -77.83% |
| Q1 2017 | -39.06% |
| Q4 2016 | -26.63% |
| Q3 2016 | 404.63% |
| Q2 2016 | 290.27% |
| Q1 2016 | -124.16% |